The 3 Most Undervalued Biotech Stocks to Buy in July 2024

There's always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow. In fact, according to Grand View Research, biotech could be worth about $3.88 trillion by 2030. After all, there's always going to be a need for biotech. Fueling even more upside is artificial intelligence, which may be able to create new drugs that can treat untreatable issues. There's even newer innovation, demand for better treatment, pharmaceutical companies strengthening pipelines, gene editing ...